Glenn Rice, Ph.D. is a Silicon Valley entrepreneur that has been involved with the founding and building of eight venture capital backed biotech and internet tech companies as founder/CEO/COO/VP Research. The companies have led to multiple FDA approved drugs in cancer, autoimmune diseases, cardiovascular, ocular and dermatology; new medical service platforms; and significant investor returns through product royalties, licensing, IPO’s or acquisitions. He is former COO of Pharmacyclics (NASDAQ:PCYC), and after restructuring and re-focusing, was purchased by Abbvie, Inc. for $21 billion within 4 years (starting valuation was $40 million). He is the former VP of Research and Board Director of NASDAQ listed ILEX Oncology, which was sold to Genzyme Corp. in 2004 for $1 billion. Prior to ILEX he was a founder and CEO of Convergence Pharmaceuticals, Inc., a Boston-based oncology company; a founder and Director of EmergingMed, an online clinical trial prequalification company; and a past Director and co-founder of C-PATH Institute, a non-profit Institute that is focused on drug development and regulatory innovation. He has also headed ~170 scientists at the Biosciences Division at SRI International (Stanford Research Institute) in Menlo Park and has significant international business experience, having established and built three biotech companies in China, as well as having extensive track records in India, Taiwan and Singapore. Dr. Rice began his career as a laboratory director at Genentech, and is an inventor on 22 patents or patent applications, authored over 75 manuscripts and book chapters, and has had extensive experience raising substantial private and public equity and corporate partnerships. Currently he is developing a new anticancer drug for children with neuroblastoma as President of MetronomX, LLC, and serving on several boards of private high tech companies as well as the board of the Silicon Valley Venture Capital Roundtable. He was appointed by the governor of California to the State Board of Trustees of the Medical Health Professionals Foundation. He is a Paul Harris Fellow of the Rotary Club and involved with a variety of other public policy groups in CA.
Dr. Yuankai SHi
Dr. Yuankai Shi is the vice president of Cancer Hospital, Chinese Academy of Medical Sciences, the director of cancer center, professor, doctoral advisor, the vice president of Chinese Society of Hematology , Chinese Medical Association , the deputy editor of Chinese Journal of Oncology, a member ofUICC-Union for International Cancer Control, the director of Chinese anti-cancer association, Beijing Association for Medical Education, the CFDA reviewer, the deputy editor of Journal of leukemia & lymphoma , a member of editorial board for more than ten other international and domestic medical magazines, a member of American Society of Clinical Oncology, American Society of Hematology, Asia Clinical Oncology Association.
Vincent Ribrag attended the University of Science and Medical School of Paris Xl between 1978 and 1985. In 1990-1991 he obtained his Maitrise of Science et Biologie Médicale in Molecular Biology, with Professor JC Kaplan. In the years 1990-1992 he also received his Diplôme d’Études Approfondies in molecular and cellular pharmacology at the Pierre et Marie Curie (Paris Vl) Univeristy with Professor Ascher. He obtained his Diplôme d’Études Secondaires in Medical Oncology and discussed a thesis (silver medal) at the Paris Xl Faculty of Medicine entitled “VIP (etoposide,ifosfamide, cisplatinum) as a salvage intensification program in relapsed or refractory Hodgkin’s disease.” Dr Ribrag is Assistant at the oncology centers of the Gustave-Roussy lnstitute and has been nominated head of the multidisciplinary committee and head of the early drug program (DITEP) in Gustave Roussy.
Among numerous experimental activities, he counts a Laboratoire in clinical pharmacology (URA 147 CNRS, U-140 INSERM) with Dr A Gouyette; works in enzymology (Cancer Res, 52: 6567€575, 1992., Garcinogenesis 14: 1279-1283, 1993., Leukemia Res 18: 829-835, 1994., leukemia and lymphoma 18: 303-310, 1995.); the ICGM: INSERM U-363 at the Hôpital Cochin in Paris (1993-1994). Enzymology and drug resistance works in leukemia (Leukemia 10:1944-1949, 1996., Anticancer Res. 17:4647-4652, 1997); the Unité INSERM U 1170: Animal MCL models and drug discovery.
Dr Ribrag is member of several international cancer societies, namely the American Association for Cancer Research (AACR), the American ociety of Clinical Oncology (ASCO), the American Society of Hematology (ASH), the Société Française de Greffe de Moelle (SFGM), the Société Française d’Hématologie (SFH), the Groupe Français des Myélodysplasies (GFM) and French intergroup on myeloproliferative diseases (FIM).
He is also part of the Lysa Scientific and Administrative Committees and of the European Scientific Committee of the Mantle Cell Lymphoma study group since 2001 and associated Head of early trials with Martin Dreyling. He is part of the board phase I trials new network within the Lysa.
Dr. Anas Younes
Chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center
Professor, Weill-Cornell Medical College, New York
Dr. Anas Younes is chief of Memorial Sloan Kettering’s Lymphoma Service, Division of Hematologic Oncology, where he is responsible for continuing to accelerate the translation of scientific discoveries into novel treatment strategies to improve the cure rate and survival of patients with Hodgkin (HL) and non-Hodgkin lymphoma (NHL). His interests include HL, NHL, developing novel targeted therapies for lymphoma, identification of biomarkers for treatment, and participation in clinical trials. He led the trials that resulted in the FDA approval of brentuximab vedotin and nivolumab for the treatment of patients with relapsed Hodgkin lymphoma. Dr. Younes has published more than 250 papers, and serves on the Scientific Advisory Board of the Lymphoma Research Foundation. He is a past member of the National Cancer Institute Lymphoma Steering Committee. He has served as the principal investigator of more than 60 clinical trials and has led the National Cancer Institute-funded SPORE (Specialized Programs of Research Excellence) in lymphoma both at M.D. Anderson Cancer Center, and most recently at MSKCC. He is also the principal investigator of a SCOR grant supported by the Leukaemia and Lymphoma Society.